Role of CNS efflux drug transporters in antiepileptic drug delivery: Overcoming CNS efflux drug transport

Advanced Drug Delivery Reviews

Volumn 64, Issue 10, 2012, Pages 943-952

  Potschka, Heidrun ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Blood brain barrier; Cyclooxygenase 2; Epilepsy; Multidrug transporter; NMDA receptor; Pharmacoresistance

Indexed keywords

BLOOD-BRAIN BARRIER; CYCLOOXYGENASE 2; EPILEPSY; MULTIDRUG TRANSPORTERS; NMDA RECEPTOR; PHARMACORESISTANCE;

BIOCHEMISTRY; BLOOD; DRUG DELIVERY; GLYCOPROTEINS; IMAGING TECHNIQUES; NONINVASIVE MEDICAL PROCEDURES;

DRUG INTERACTIONS;

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ANTICONVULSIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; CARRIER PROTEIN; CELECOXIB; CLONAZEPAM; CYCLOOXYGENASE 2 INHIBITOR; DIAZEPAM; DIZOCILPINE; DRUG TRANSPORTER; ETHOSUXIMIDE; GABAPENTIN; GLYCOPROTEIN P; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; PHENOBARBITAL; PHENYTOIN; RIBOZYME; SMALL INTERFERING RNA; TARIQUIDAR; TOPIRAMATE; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL C 11; XENOBIOTIC AGENT; ZONISAMIDE;

ADD ON THERAPY; BLOOD BRAIN BARRIER; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM; DRUG PENETRATION; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TRANSPORT; ENCAPSULATION; EPILEPSY; HUMAN; IMAGING; LUNG NON SMALL CELL CANCER; NON INVASIVE MEASUREMENT; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RODENT; SEIZURE; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTICONVULSANTS; BRAIN; EPILEPSY; HUMANS; MEMBRANE TRANSPORT PROTEINS;

EID: 84862906610     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.12.007     Document Type: Review

References (133)

1. Potschka H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies?. Epilepsia 2010, 51:1333-1347.
2. Coley H.M. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol. Biol. 2010, 596:341-358.
3. Fox E., Bates S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert. Rev. Anticancer. Ther. 2007, 7:447-459.
4. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol. Ther. 2010, 125:118-127.
5. Baumert C., Hilgeroth A. Recent advances in the development of P-gp inhibitors. Anticancer Agents Med. Chem. 2009, 9:415-436.
6. Shukla S., Ohnuma S., Ambudkar S.V. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr. Drug Targets 2011, 12:621-630.
7. Bates S.F., Chen C., Robey R., Kang M., Figg W.D., Fojo T. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found. Symp. 2002, 243:83-96. discussion 96-102, 180-105.
8. Loscher W., Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005, 2:86-98.
9. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10:159-165.
10. Shukla S., Ohnuma S., Ambudkar S.V. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr. Drug Targets 2010, 12(5):621-630.
11. Brandt C., Bethmann K., Gastens A.M., Loscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol. Dis. 2006, 24:202-211.
12. van Vliet E.A., van Schaik R., Edelbroek P.M., Redeker S., Aronica E., Wadman W.J., Marchi N., Vezzani A., Gorter J.A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006, 47:672-680.
13. Potschka H., Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001, 42:1231-1240.
14. Potschka H., Fedrowitz M., Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001, 12:3557-3560.
15. Iannetti P., Parisi P., Spalice A., Ruggieri M., Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res. 2009, 85:89-95.
16. Iannetti P., Spalice A., Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005, 46:967-969.
17. Summers M.A., Moore J.L., McAuley J.W. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann. Pharmacother. 2004, 38:1631-1634.
18. Schmitt F.C., Dehnicke C., Merschhemke M., Meencke H.J. Verapamil attenuates the malignant treatment course in recurrent status epilepticus. Epilepsy Behav. 2010, 17:565-568.
19. Macphee G.J., McInnes G.T., Thompson G.G., Brodie M.J. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1986, 1:700-703.
20. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003, 2:473-481.
21. Potschka H., Fedrowitz M., Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J. Pharmacol. Exp. Ther. 2003, 306:124-131.
22. Luna-Tortos C., Fedrowitz M., Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 55:1364-1375.
23. van Vliet E.A., van Schaik R., Edelbroek P.M., Voskuyl R.A., Redeker S., Aronica E., Wadman W.J., Gorter J.A. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J. Pharmacol. Exp. Ther. 2007, 322:141-147.
24. Huls M., Russel F.G., Masereeuw R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J. Pharmacol. Exp. Ther. 2009, 328:3-9.
25. Lee G., Bendayan R. Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm. Res. 2004, 21:1313-1330.
26. Lai B.C., Marion S.A., Teschke K., Tsui J.K. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat. Disord. 2002, 8:297-309.
27. Drozdzik M., Bialecka M., Mysliwiec K., Honczarenko K., Stankiewicz J., Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003, 13:259-263.
28. Furuno T., Landi M.T., Ceroni M., Caporaso N., Bernucci I., Nappi G., Martignoni E., Schaeffeler E., Eichelbaum M., Schwab M., Zanger U.M. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002, 12:529-534.
29. Lee C.G., Tang K., Cheung Y.B., Wong L.P., Tan C., Shen H., Zhao Y., Pavanni R., Lee E.J., Wong M.C., Chong S.S., Tan E.K. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J. Med. Genet. 2004, 41:e60.
30. Tan E.K., Chan D.K., Ng P.W., Woo J., Teo Y.Y., Tang K., Wong L.P., Chong S.S., Tan C., Shen H., Zhao Y., Lee C.G. Effect of MDR1 haplotype on risk of Parkinson disease. Arch. Neurol. 2005, 62:460-464.
31. Zschiedrich K., Konig I.R., Bruggemann N., Kock N., Kasten M., Leenders K.L., Kostic V., Vieregge P., Ziegler A., Klein C., Lohmann K. MDR1 variants and risk of Parkinson disease. Association with pesticide exposure?. J. Neurol. 2009, 256:115-120.
32. Bartels A.L., Willemsen A.T., Kortekaas R., de Jong B.M., de Vries R., de Klerk O., van Oostrom J.C., Portman A., Leenders K.L. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J. Neural Transm. 2008, 115:1001-1009.
33. Bartels A.L., Kortekaas R., Bart J., Willemsen A.T., de Klerk O.L., de Vries J.J., van Oostrom J.C., Leenders K.L. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol. Aging 2008, 33(11):1818-1824.
34. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., Hendrikse N.H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 2005, 57:176-179.
35. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., Jiang H., Prior J.L., Sagare A., Bales K.R., Paul S.M., Zlokovic B.V., Piwnica-Worms D., Holtzman D.M. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2005, 115:3285-3290.
36. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., Kunert-Keil C., Walker L.C., Warzok R.W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002, 12:535-541.
37. Wijesuriya H.C., Bullock J.Y., Faull R.L., Hladky S.B., Barrand M.A. ABC efflux transporters in brain vasculature of Alzheimer's subjects. Brain Res. 2010, 1358:228-238.
38. Fromm M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 2004, 25:423-429.
39. Yamamoto-Furusho J.K. Genetic factors associated with the development of inflammatory bowel disease. World J. Gastroenterol. 2007, 13:5594-5597.
40. Luna-Tortos C., Fedrowitz M., Loscher W. Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 2010, 58:1019-1032.
41. Cerveny L., Pavek P., Malakova J., Staud F., Fendrich Z. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. Epilepsia 2006, 47:461-468.
42. Lage H. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr. Drug Targets 2006, 7:813-821.
43. Stege A., Kruhn A., Lage H. Overcoming multidrug resistance by RNA interference. Methods Mol. Biol. 2010, 596:447-465.
44. Fuest C., Bankstahl M., Winter P., Helm M., Pekcec A., Potschka H. In vivo down-regulation of mouse brain capillary P-glycoprotein: a preliminary investigation. Neurosci. Lett. 2009, 464:47-51.
45. Hartz A.M., Notenboom S., Bauer B. Signaling to P-glycoprotein - a new therapeutic target to treat drug-resistant epilepsy?. Drug News Perspect. 2009, 22:393-397.
46. Miller D.S. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci. 2010, 31:246-254.
47. Shukla S.J., Sakamuru S., Huang R., Moeller T.A., Shinn P., Vanleer D., Auld D.S., Austin C.P., Xia M. Identification of clinically used drugs that activate pregnane X receptors. Drug Metab. Dispos. 2011, 39:151-159.
48. Masuyama H., Suwaki N., Tateishi Y., Nakatsukasa H., Segawa T., Hiramatsu Y. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol. Endocrinol. 2005, 19:1170-1180.
49. Wang H., LeCluyse E.L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 2003, 42:1331-1357.
50. Xiao L., Nickbarg E., Wang W., Thomas A., Ziebell M., Prosise W.W., Lesburg C.A., Taremi S.S., Gerlach V.L., Le H.V., Cheng K.C. Evaluation of in vitro PXR-based assays and in silico modeling approaches for understanding the binding of a structurally diverse set of drugs to PXR. Biochem. Pharmacol. 2010, 81(5):669-679.
51. Loo T.W., Clarke D.M. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol. 2005, 206:173-185.
52. Kimura Y., Morita S.Y., Matsuo M., Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 2007, 98:1303-1310.
53. Christians U., Schmitz V., Haschke M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin. Drug Metab. Toxicol. 2005, 1:641-654.
54. Harmsen S., Meijerman I., Febus C.L., Maas-Bakker R.F., Beijnen J.H., Schellens J.H. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother. Pharmacol. 2010, 66:765-771.
55. Masuyama H., Nakatsukasa H., Takamoto N., Hiramatsu Y. Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol. Pharmacol. 2007, 72:1045-1053.
56. Rizzi M., Caccia S., Guiso G., Richichi C., Gorter J.A., Aronica E., Aliprandi M., Bagnati R., Fanelli R., D'Incalci M., Samanin R., Vezzani A. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J. Neurosci. 2002, 22:5833-5839.
57. Ambroziak K., Kuteykin-Teplyakov K., Luna-Tortos C., Al-Falah M., Fedrowitz M., Loscher W. Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines. Eur. J. Pharmacol. 2010, 628:57-66.
58. Seegers U., Potschka H., Loscher W. Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur. J. Pharmacol. 2002, 451:149-155.
59. Lombardo L., Pellitteri R., Balazy M., Cardile V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr. Neurovasc. Res. 2008, 5:82-92.
60. Wen T., Liu Y.C., Yang H.W., Liu H.Y., Liu X.D., Wang G.J., Xie L. Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain. J. Neurol. Sci. 2008, 270:99-106.
61. Wang-Tilz Y., Tilz C., Wang B., Tilz G.P., Stefan H. Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy. Epilepsia 2006, 47:233-239.
62. Jing X., Liu X., Wen T., Xie S., Yao D., Wang G., Xie L. Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats. Br. J. Pharmacol. 2010, 159:1511-1522.
63. Mohanraj R., Brodie M.J. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur. J. Neurol. 2006, 13:277-282.
64. Rogawski M.A., Johnson M.R. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr. 2008, 8:127-130.
65. Bauer B., Hartz A.M., Pekcec A., Toellner K., Miller D.S., Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol. 2008, 73:1444-1453.
66. Pekcec A., Unkruer B., Schlichtiger J., Soerensen J., Hartz A.M., Bauer B., van Vliet E.A., Gorter J.A., Potschka H. Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J. Pharmacol. Exp. Ther. 2009, 330:939-947.
67. Bankstahl J.P., Hoffmann K., Bethmann K., Loscher W. Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain. Neuropharmacology 2008, 54:1006-1016.
68. Loscher W., Honack D. The novel competitive N-methyl-d-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotonin1A receptors. J. Pharmacol. Exp. Ther. 1991, 257:1146-1153.
69. Loscher W., Honack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-d-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J. Pharmacol. Exp. Ther. 1991, 256:432-440.
70. Wlaz P., Ebert U., Potschka H., Loscher W. Electrical but not chemical kindling increases sensitivity to some phencyclidine-like behavioral effects induced by the competitive NMDA receptor antagonist D-CPPene in rats. Eur. J. Pharmacol. 1998, 353:177-189.
71. Potschka H., Loscher W. Corneal kindling in mice: behavioral and pharmacological differences to conventional kindling. Epilepsy Res. 1999, 37:109-120.
72. Sveinbjornsdottir S., Sander J.W., Upton D., Thompson P.J., Patsalos P.N., Hirt D., Emre M., Lowe D., Duncan J.S. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 1993, 16:165-174.
73. Zibell G., Unkruer B., Pekcec A., Hartz A.M., Bauer B., Miller D.S., Potschka H. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009, 56:849-855.
74. van Vliet E.A., Zibell G., Pekcec A., Schlichtiger J., Edelbroek P.M., Holtman L., Aronica E., Gorter J.A., Potschka H. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010, 58:404-412.
75. Schlichtiger J., Pekcec A., Bartmann H., Winter P., Fuest C., Soerensen J., Potschka H. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br. J. Pharmacol. 2010, 160:1062-1071.
76. Brune K. Safety of anti-inflammatory treatment-new ways of thinking. Rheumatology (Oxford) 2004, 43(Suppl. 1):i16-i20.
77. Akarsu E.S., Ozdayi S., Algan E., Ulupinar F. The neuronal excitability time-dependently changes after lipopolysaccharide administration in mice: possible role of cyclooxygenase-2 induction. Epilepsy Res. 2006, 71:181-187.
78. Baik E.J., Kim E.J., Lee S.H., Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. 1999, 843:118-129.
79. Kim E.J., Lee J.E., Kwon K.J., Lee S.H., Moon C.H., Baik E.J. Differential roles of cyclooxygenase isoforms after kainic acid-induced prostaglandin E(2) production and neurodegeneration in cortical and hippocampal cell cultures. Brain Res. 2001, 908:1-9.
80. Kim H.J., Chung J.I., Lee S.H., Jung Y.S., Moon C.H., Baik E.J. Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res. 2008, 1193:153-161.
81. Toscano C.D., Kingsley P.J., Marnett L.J., Bosetti F. NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology 2008, 29:1114-1120.
82. Holtman L., van Vliet E.A., van Schaik R., Queiroz C.M., Aronica E., Gorter J.A. Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy. Epilepsy Res. 2009, 84:56-66.
83. Marchi N., Betto G., Fazio V., Fan Q., Ghosh C., Machado A., Janigro D. Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema. Epilepsia 2009, 50:664-677.
84. Granata T., Marchi N., Carlton E., Ghosh C., Gonzalez-Martinez J., Alexopoulos A.V., Janigro D. Management of the patient with medically refractory epilepsy. Expert. Rev. Neurother. 2009, 9:1791-1802.
85. Fisher R.S., Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 2002, 16:579-593.
86. de Boer A.G., Gaillard P.J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 2007, 47:323-355.
87. Couvreur P., Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 2006, 23:1417-1450.
88. Barratt G.M. Therapeutic applications of colloidal drug carriers. Pharm. Sci. Technol. Today 2000, 3:163-171.
89. Lockman P.R., Mumper R.J., Khan M.A., Allen D.D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 2002, 28:1-13.
90. Yasukawa T., Ogura Y., Sakurai E., Tabata Y., Kimura H. Intraocular sustained drug delivery using implantable polymeric devices. Adv. Drug Deliv. Rev. 2005, 57:2033-2046.
91. Bennewitz M.F., Saltzman W.M. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics 2009, 6:323-336.
92. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5:505-515.
93. van Vlerken L.E., Vyas T.K., Amiji M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 2007, 24:1405-1414.
94. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42:419-436.
95. Potschka H. Targeting the brain-surmounting or bypassing the blood-brain barrier. Handb. Exp. Pharmacol. 2010, 411-431.
96. Friese A., Seiller E., Quack G., Lorenz B., Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 2000, 49:103-109.
97. Fresta M., Cavallaro G., Giammona G., Wehrli E., Puglisi G. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials 1996, 17:751-758.
98. Jeong Y.I., Cheon J.B., Kim S.H., Nah J.W., Lee Y.M., Sung Y.K., Akaike T., Cho C.S. Clonazepam release from core-shell type nanoparticles in vitro. J. Control. Release 1998, 51:169-178.
99. Nah J.W., Paek Y.W., Jeong Y.I., Kim D.W., Cho C.S., Kim S.H., Kim M.Y. Clonazepam release from poly(dl-lactide-co-glycolide) nanoparticles prepared by dialysis method. Arch. Pharm. Res. 1998, 21:418-422.
100. Ryu J., Jeong Y.I., Kim I.S., Lee J.H., Nah J.W., Kim S.H. Clonazepam release from core-shell type nanoparticles of poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) triblock copolymers. Int. J. Pharm. 2000, 200:231-242.
101. Abdelbary G., Fahmy R.H. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech 2009, 10:211-219.
102. Thakur R., Gupta R.B. Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process. Int. J. Pharm. 2006, 308:190-199.
103. Darius J., Meyer F.P., Sabel B.A., Schroeder U. Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice. J. Pharm. Pharmacol. 2000, 52:1043-1047.
104. Sznitowska M., Gajewska M., Janicki S., Radwanska A., Lukowski G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur. J. Pharm. Biopharm. 2001, 52:159-163.
105. Douroumis D., Fahr A. Stable carbamazepine colloidal systems using the cosolvent technique. Eur. J. Pharm. Sci. 2007, 30:367-374.
106. Varshosaz J., Eskandari S., Tabakhian M. Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design. Pharm. Dev. Technol. 2010, 15:89-96.
107. Kemper E.M., Boogerd W., Thuis I., Beijnen J.H., van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?. Cancer Treat. Rev. 2004, 30:415-423.
108. Rapoport S.I. Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin. Investig. Drugs 2001, 10:1809-1818.
109. Marchi N., Angelov L., Masaryk T., Fazio V., Granata T., Hernandez N., Hallene K., Diglaw T., Franic L., Najm I., Janigro D. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007, 48:732-742.
110. van Vliet E.A., da Costa Araujo S., Redeker S., van Schaik R., Aronica E., Gorter J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007, 130:521-534.
111. Seiffert E., Dreier J.P., Ivens S., Bechmann I., Tomkins O., Heinemann U., Friedman A. Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J. Neurosci. 2004, 24:7829-7836.
112. Shlosberg D., Benifla M., Kaufer D., Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat. Rev. Neurol. 2010, 6:393-403.
113. Serralta A., Barcia J.A., Ortiz P., Duran C., Hernandez M.E., Alos M. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model. Epilepsy Res. 2006, 70:15-26.
114. Oommen J., Kraus A.C., Fisher R.S. Intraventricular administration of gabapentin in the rat increases flurothyl seizure threshold. Neurosci. Lett. 2007, 417:308-311.
115. Rogawski M.A. Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 2009, 6:344-351.
116. Sawyer A.J., Piepmeier J.M., Saltzman W.M. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J. Biol. Med. 2006, 79:141-152.
117. King M., Su W., Chang A., Zuckerman A., Pasternak G.W. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat. Neurosci. 2001, 4:268-274.
118. Ugwoke M.I., Verbeke N., Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 2001, 53:3-21.
119. Wolfe T.R., Macfarlane T.C. Intranasal midazolam therapy for pediatric status epilepticus. Am. J. Emerg. Med. 2006, 24:343-346.
120. Wermeling D.P. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics 2009, 6:352-358.
121. Czapp M., Bankstahl J.P., Zibell G., Potschka H. Brain penetration and anticonvulsant efficacy of intranasal phenobarbital in rats. Epilepsia 2008, 49:1142-1150.
122. Merkus F.W., van den Berg M.P. Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory. Drugs R&D 2007, 8:133-144.
123. Kwan P., Li H.M., Al-Jufairi E., Abdulla R., Gonzales M., Kaye A.H., Szoeke C., Ng H.K., Wong K.S., O'Brien T.J. Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol. Dis. 2010, 39:192-197.
124. Potschka H. Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics 2010, 11:1427-1438.
125. Loscher W., Langer O. Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy. Curr. Top. Med. Chem. 2010, 10:1785-1791.
126. Langer O., Bauer M., Hammers A., Karch R., Pataraia E., Koepp M.J., Abrahim A., Luurtsema G., Brunner M., Sunder-Plassmann R., Zimprich F., Joukhadar C., Gentzsch S., Dudczak R., Kletter K., Muller M., Baumgartner C. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia 2007, 48:1774-1784.
127. Syvanen S., Hooker A., Rahman O., Wilking H., Blomquist G., Langstrom B., Bergstrom M., Hammarlund-Udenaes M. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J. Pharm. Sci. 2008, 97:5386-5400.
128. Hendrikse N.H., Schinkel A.H., de Vries E.G., Fluks E., Van der Graaf W.T., Willemsen A.T., Vaalburg W., Franssen E.J. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol. 1998, 124:1413-1418.
129. Bankstahl J.P., Kuntner C., Abrahim A., Karch R., Stanek J., Wanek T., Wadsak W., Kletter K., Muller M., Loscher W., Langer O. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J. Nucl. Med. 2008, 49:1328-1335.
130. Wagner C.C., Bauer M., Karch R., Feurstein T., Kopp S., Chiba P., Kletter K., Loscher W., Muller M., Zeitlinger M., Langer O. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J. Nucl. Med. 2009, 50(12):1954-1961.
131. la Fougere C., Boning G., Bartmann H., Wangler B., Nowak S., Just T., Wagner E., Winter P., Rominger A., Forster S., Gildehaus F.J., Rosa-Neto P., Minuzzi L., Bartenstein P., Potschka H., Cumming P. Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. NeuroImage 2010, 49:1406-1415.
132. Bartmann H., Fuest C., la Fougere C., Xiong G., Just T., Schlichtiger J., Winter P., Boning G., Wangler B., Pekcec A., Soerensen J., Bartenstein P., Cumming P., Potschka H. Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia 2010, 51:1780-1790.
133. Jambroszyk M., Tipold A., Potschka H. Add-on treatment with verapamil in pharmacoresistant canine epilepsy. Epilepsia 2011, 52(2):284-291.